Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. According to the study, treatment produced dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance.
The company said the findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis. Management noted that the biological pathways targeted by Telomir-Zn have been implicated in both metabolic disease and cancer, and said the results complement the company’s recently FDA-cleared Phase 1/2 clinical program evaluating the drug in patients with advanced or metastatic triple-negative breast cancer. For more details, the full press release is available at https://ibn.fm/BoK2F.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO.
The publication of these data is significant because it expands the potential therapeutic applications of Telomir-Zn beyond oncology into metabolic diseases, a major global health concern. Type 2 diabetes affects hundreds of millions worldwide, and current treatments often fail to address underlying insulin resistance. If these findings translate to humans, Telomir-Zn could offer a novel approach to restoring insulin sensitivity by targeting metal homeostasis, a pathway not currently exploited by existing diabetes therapies.
The implications for Telomir Pharmaceuticals are substantial. Positive preclinical data in a metabolic disease model could support the expansion of the company’s pipeline and attract partnerships or funding for further development. Moreover, the data strengthen the scientific rationale for the drug’s mechanism, which may also have relevance in aging and degenerative diseases. For investors, the publication adds credibility to the company’s technology platform and could influence market perception as Telomir moves toward clinical trials in diabetes.
For the broader biomedical community, the study highlights the role of metal homeostasis in insulin signaling and glucose metabolism, opening new avenues for research. The zebrafish model used is well-established for studying metabolic diseases and provides a cost-effective platform for screening potential therapeutics. The dose-dependent effects observed suggest a clear pharmacological response, supporting the potential for clinical translation.
